The Ben Towne Center’s mission is to translate scientific discoveries into innovative therapies that cure childhood cancer with minimal side effects and improve survivors’ quality of life.
We are spearheading treatments that use the immune system to eliminate cancer, without chemotherapy or radiation. Our goal is to render today’s therapies obsolete until treating childhood cancer is no different than treating an everyday virus.
Our clinical trials are helping children with acute lymphoblastic leukemia achieve complete remission.
You are helping us create a future where pediatric cancer treatment is less toxic and far less harmful
Dr. Julie Park is leading one of the world’s first clinical studies of immunotherapy for neuroblastoma – the deadliest childhood cancer.
You can help bring an end to childhood cancer all over the world, by supporting our Strong Against Cancer fundraising initiative.
Our researchers have started the first round of clinical trials exploring a potential cure.
Help us answer questions about childhood health and illness, and help other children in the future. Learn more.
Developing groundbreaking cancer treatments takes more than just the right ideas. It also takes the right people.
Please visit Seattle Children’s careers page to learn about current openings.
For information about potential opportunities in the Ben Towne Center, email us.
First-in-human clinical trial aims to extend remission for children and young adults with leukemia treated with T-cell immunotherapy (This story appeared in over 230 news outlets) – 05.09.17 – MarketWatch Building on PLAT-02, a phase 1 pilot study, PLAT-03, will examine the feasibility and safety of administering a second T-cell product intended to increase the long-term persistence of the patient's chimeric antigen receptor (CAR) T cells that were reprogrammed to detect and destroy cancer. "We're pleased to now be able to offer patients who have lost or are at risk of losing their cancer-fighting T cells an option that will hopefully lead to them achieving long-term remission," said Dr. Colleen Annesley, an oncologist at Seattle Children's and the lead investigator of the PLAT-03 trial. Drs. Rebecca Gardner and Mike Jensen are also mentioned in the article.
NIH awards Emory team $12.6 million for improved post-transplant regimens – 05.19.17 – Emory The National Institute of Allergy and Infectious Diseases has awarded Emory transplant researchers $12.6 million over five years to investigate improved post-transplant drug regimens for organ transplant recipients. The project team includes Dr. Leslie Kean of Seattle Children’s Hospital and the University of Washington.
Seattle Children's brings first-of-its-kind precision medicine clinical trial to inflammatory bowel disease, bone marrow transplant patients (This story appeared in over 170 news outlets) – 05.23.17 – MarketWatch In an effort to find new strategies to personalize treatment for pediatric patients, Seattle Children's has opened the PREDICT (Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation) trial. It is the first clinical trial applying next-generation T-cell receptor sequencing and single-cell gene expression analysis to better understand how the immune system drives both inflammatory bowel disease in pediatric autoimmunity patients and graft-versus host disease in pediatric bone marrow transplant patients. Dr. Leslie Kean is the trial's principal investigator who leads a lab focused on T-cell immunology and is the associate director of the Ben Towne Center for Childhood Cancer Research at Seattle Children's Research Institute.
Email the BTCCCR
1100 Olive Way, Suite 100
Seattle, WA 98101
PO Box 5371
Seattle, WA 98145-5005